Alcon (ALC)

• Market cap: $42.9B
• 1 day: -2.22%
• 5 days: -5.47%
• 1 month: -3.80%
• 3 months: 3.14%
• 6 months: -11.87%
• Year to date: 4.03%
• 1 year: -0.60%
• 5 years: 63.42%
• 10 years: 49.57%
• Sector: Healthcare
• Industry: Ophthalmic Goods

About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Employees: 25,599

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

14% more first-time investments, than exits

New positions opened: 80 | Existing positions closed: 70

4.27% more ownership

Funds ownership: 49.55% [Q3] → 53.82% (+4.27%) [Q4]

1% less funds holding

Funds holding: 645 [Q3] → 639 (-6) [Q4]

8% less capital invested

Capital invested by funds: $24.5B [Q3] → $22.4B (-$2.01B) [Q4]

12% less repeat investments, than reductions

Existing positions increased: 201 | Existing positions reduced: 228

20% less call options, than puts

Call options by funds: $164M | Put options by funds: $205M

29% less funds holding in top 10

Funds holding in top 10: 17 [Q3] → 12 (-5) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $105 21% upside
• Avg. target: $107 23% upside
• High target: $108 24% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Baird Jeff Johnson 36% 1-year accuracy 10 / 28 met price target	24% upside $108	Outperform Maintained	27 Feb 2025
Needham David Saxon 25% 1-year accuracy 16 / 65 met price target	23% upside $107	Buy Maintained	27 Feb 2025
Keybanc Brett Fishbin 25% 1-year accuracy 4 / 16 met price target	21% upside $105	Overweight Maintained	24 Jan 2025